Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
116 hedge funds and large institutions have $693M invested in Adverum Biotechnologies in 2019 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 33 increasing their positions, 38 reducing their positions, and 13 closing their positions.
267% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $3.69M
160% more capital invested
Capital invested by funds: $267M → $693M (+$426M)
138% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 13
17% more funds holding
Funds holding: 99 → 116 (+17)
1.71% more ownership
Funds ownership: 7.6% → 9.31% (+1.7%)
13% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$11.7M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$8.81M |
| 3 |
VMI
VHCP Management III
New York
|
+$8.34M |
| 4 |
Goldman Sachs
New York
|
+$5.38M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$15.2M |
| 2 |
Renaissance Technologies
New York
|
-$10.9M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$5.18M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5.08M |
| 5 |
Primecap Management
Pasadena,
California
|
-$2.48M |
ADVM Hedge Fund Activity: Q4 2019 in Review
116 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q4 2019, worth a combined $693M — up 160% from $267M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ADVM positions and 13 closed out — a net gain of 18 holders — while 33 added to existing stakes and 38 trimmed.
The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $11.7M. The largest seller was State Street, cutting an estimated $15.2M.
- 116 institutional investors held Adverum Biotechnologies (ADVM) as of Q4 2019, up from 99 in Q3 2019.
- Funds reported $693M of Adverum Biotechnologies stock for Q4 2019, up 160% quarter-over-quarter.
- 31 funds opened new Adverum Biotechnologies positions in Q4 2019 and 13 closed out, a net change of +18 holders.
- The largest Adverum Biotechnologies buyer in Q4 2019 was Acuta Capital Partners, an estimated $11.7M added.
- The largest Adverum Biotechnologies seller in Q4 2019 was State Street, an estimated $15.2M sold.
Based on aggregated 13F filings for Q4 2019.